Novartis dives even deeper into radioligands, notching licensing deal with iTheranostics for multiple compounds

Novartis captured attention last week for its Phase III prostate cancer win with a radioligand therapy it picked up for $2 billion back in 2018. Now, Novartis is doubling down on the field.

Novartis will acquire development and commercial rights to two iTheranostics radioligand therapies targeting fibroblast activation proteins on the surface of tumor cells, the Swiss drugmaker said Tuesday. The deal covers candidates FAPI-46 and FAPI-74.